药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Allylprodine
Dihydralazine
Dihydroergocristine may decrease the antihypertensive activities of Dihydralazine.
Allylprodine
Cicletanine
Dihydroergocristine may decrease the antihypertensive activities of Cicletanine.
Allylprodine
Ketanserin
Dihydroergocristine may decrease the antihypertensive activities of Ketanserin.
Allylprodine
BQ-123
Dihydroergocristine may decrease the antihypertensive activities of BQ-123.
Allylprodine
Imidapril
Dihydroergocristine may decrease the antihypertensive activities of Imidapril.
Allylprodine
Angiotensin 1-7
Dihydroergocristine may decrease the antihypertensive activities of Angiotensin 1-7.
Allylprodine
Enalaprilat
Dihydroergocristine may decrease the antihypertensive activities of Enalaprilat.
Allylprodine
Nicorandil
Dihydroergocristine may decrease the antihypertensive activities of Nicorandil.
Allylprodine
Trimazosin
Dihydroergocristine may decrease the antihypertensive activities of Trimazosin.
Allylprodine
Hexamethonium
Dihydroergocristine may decrease the antihypertensive activities of Hexamethonium.
Allylprodine
Ferulic acid
Dihydroergocristine may decrease the antihypertensive activities of Ferulic acid.
Allylprodine
Diethylnorspermine
Dihydroergocristine may decrease the antihypertensive activities of Diethylnorspermine.
Allylprodine
Tienilic acid
Dihydroergocristine may decrease the antihypertensive activities of Tienilic acid.
Allylprodine
Pralsetinib
Pralsetinib may decrease the excretion rate of Dihydroergocristine which could result in a higher serum level.
Allylprodine
Valinomycin
Valinomycin may decrease the excretion rate of Dihydroergocristine which could result in a higher serum level.
Boldenone
Ilaprazole
Ilaprazole can cause a decrease in the absorption of Ferrous sulfate anhydrous resulting in a reduced serum concentration and potentially a decrease in efficacy.
Boldenone
Dexrabeprazole
Dexrabeprazole can cause a decrease in the absorption of Ferrous sulfate anhydrous resulting in a reduced serum concentration and potentially a decrease in efficacy.
Boldenone
Dexlansoprazole
Dexlansoprazole can cause a decrease in the absorption of Ferrous sulfate anhydrous resulting in a reduced serum concentration and potentially a decrease in efficacy.
Boldenone
Ferric derisomaltose
The absorption of Ferrous sulfate anhydrous can be decreased when combined with Ferric derisomaltose.
Boldenone
Raltegravir
The serum concentration of Raltegravir can be decreased when it is combined with Ferrous sulfate anhydrous.